Fibrocell Science Inc. is no longer an independently traded public corporate entity, as the company was acquired entirely by Castle Creek Biosciences years ago, resulting in the delisting of its historical shares from public exchanges. Consequently, live active trading quotes are unavailable for the legacy ticker, and historical pricing records remain archived on financial platforms solely for retrospective reference purposes, reflecting its transition into a privately held cell and gene therapy enterprise.